BioCentury | Jun 19, 2019
Distillery Therapeutics

Inhibiting miR-181a and miR-181b could treat obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Inhibition of miR-181a and miR-181b or treatment with indole -- a negative regulator of the two microRNAs -- could help treat obesity. Expression of miR-181a2 and miR-181b2 in white adipose...
BioCentury | Jan 23, 2018
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and mouse studies suggest inhibiting miR-181a or NFAT5 could help treat islet autoimmunity, a precursor to Type I diabetes. In blood samples from children of Type I diabetes patients, T cell...
BioCentury | Aug 30, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute lymphoblastic leukemia (ALL) Notch 1 (NOTCH1); microRNA-181a (miR-181a); miR-181b-1 Mouse and cell culture studies suggest inhibiting miR-181a and miR-181b-1 could help treat NOTCH1 pathway-driven...
BioCentury | Jun 7, 2012
Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation MicroRNA-181b (miR-181b) Patient sample and mouse studies suggest agonizing miR-181b could help treat inflammation. In a mouse model of endotoxic...
Items per page:
1 - 4 of 4